Safety of Four Treatment Regimens in Early Rheumatoid Arthritis
June 2017
in “
Poster presentations
”
New to Prednisolone? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this study, the safety profiles of four treatments for early rheumatoid arthritis were assessed over one year, and the most serious side effects necessitating treatment discontinuation were noted in the leflunomide group, whereas no such withdrawals occurred in the methotrexate plus prednisolone group.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study compared the safety of four treatment regimens in 141 patients with early rheumatoid arthritis over one year. The regimens included methotrexate (MTX), MTX plus prednisolone (MTX-P), MTX-P plus methylprednisolone (MTX-P-MP), and leflunomide (LEF). Side effects were similar across groups, with 9 patients in each group experiencing them. Six patients discontinued therapy due to side effects, most frequently in the LEF group. The MTX-P group had no therapy withdrawals. Overall, side effects were generally moderate or minimal, and the safety profile was consistent across all groups.
